The COVID-19 Payer Pulse Survey

Posted by Ed Schoonveld on Mon, Apr 27, 2020

Many of our clients have been asking us about the impact of COVID-19 on coverage approvals and the management of prescription drugs. We used our rapid response PayerLIVE survey instrument to get some reactions from U.S., EU and Canadian payers with respect to the impact of COVID-19 on their functioning, pharma industry relationships and expectations for the near future.


>
Read More

Rising unemployment and its impact on pharma's top and bottom line

Posted by Ricky Yuen on Mon, Apr 20, 2020

Kyle Harpole and Nishank Kanungo co-wrote this blog post with Ricky Yuen.

Access COVID-19 resources

Unemployment claims are at 22 million and climbing due to the COVID-19 pandemic, and like the great recession of 2008, rising unemployment means that patients will shift from employer-sponsored coverage to ACA health exchange plans or Medicaid, or become uninsured. In addition, the financial constraints on payers and providers due to this event are unprecedented, all with the backdrop of upcoming elections and other reforms already being planned. Given this seismic impact on the healthcare landscape, U.S. market access organizations will need to start thinking about the lasting impact of COVID-19 on market access analytics, contracting and gross-to-net (GTN).


>
Read More

The Price (or Lack) of Global Health

Posted by Ed Schoonveld on Fri, Dec 20, 2019

Governments, private health insurers and employers worldwide are deeply concerned about the increasing cost of healthcare. U.S. healthcare cost as a share of GDP has nearly tripled from 1970 to 2017, resulting in a growing societal burden.


>
Read More

Accelerating Market Access: Three Trends Shaping Pharma’s Future

Posted by Ed Schoonveld on Mon, Dec 16, 2019

Dean Hakanson co-wrote this blog post with Ed Schoonveld.

Is the demand for value-based care merely superficial? Are the industry’s decision-making and incentive systems built to encourage clinical innovation? How will pharma companies rethink their pipelines to improve poor commercialization efforts?


>
Read More

The 2019 STAT Summit: ‘You Don’t Burn the House Down to Get Rid of Rats’

Posted by Ed Schoonveld on Tue, Nov 26, 2019

Many senior leaders in the healthcare and pharmaceutical space gathered at the inaugural STAT Summit on Nov. 21st at the MIT campus in Cambridge, Mass. The invitation-only summit featured an interesting mix of exciting medical scientific advances, including bionic limbs, artificial intelligence, the impact of real-world evidence on drug development, and patient testimonials regarding some great medical and pharmaceutical innovations.


>
Read More